Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (RARE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rare · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Ultragenyx Pharmaceutical Inc. (RARE) measures how much investors pay for each dollar of the company's trailing earnings. RARE's current PE ratio of N/A is calculated by dividing its stock price of $21.59 by its TTM earnings per share of -$6.06.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Ultragenyx Pharmaceutical Inc.You RARE | $2.1B | N/A | — | -$6.06 |
 Ascentage Pharma Group International AAPG | $1.6B | N/A | — | -$13.58 |
 Apogee Therapeutics, Inc. APGE | $5.1B | N/A | — | -$4.22 |
 Celcuity Inc. CELC | $4.3B | N/A | — | -$3.37 |
 CG Oncology, Inc. Common stock CGON | $4.8B | N/A | — | -$2.08 |
 Centessa Pharmaceuticals plc CNTA | $6.1B | N/A | — | -$1.46 |
 Dyne Therapeutics, Inc. DYN | $2.8B | N/A | — | -$3.47 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-5.83 | — | |
2024-12-31 FY2024 | — | $-6.29 | — | |
2023-12-31 FY2023 | — | $-8.25 | — | |
2022-12-31 FY2022 | — | $-10.12 | — | |
2021-12-31 FY2021 | — | $-6.70 | — | |
2020-12-31 FY2020 | — | $-3.07 | — | |
2019-12-31 FY2019 | — | $-7.12 | — | |
2018-12-31 FY2018 | — | $-3.97 | — | |
2017-12-31 FY2017 | — | $-7.12 | — | |
2016-12-31 FY2016 | — | $-6.21 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Ultragenyx Pharmaceutical Inc. (RARE) measures how much investors pay for each dollar of the company's trailing earnings. RARE's current PE ratio of N/A is calculated by dividing its stock price of $21.59 by its TTM earnings per share of -$6.06.
Frequently asked questions
RARE pe ratio · 6 questionsRARE's current PE ratio is N/A as of 2026-06-08, based on a stock price of $21.59 and TTM EPS of -$6.06. Data sourced from Financial Modeling Prep via RARE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Ultragenyx Pharmaceutical Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08